Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.74 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.74 |
| ▸ | FABP3 | P05413 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL326926 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL672430 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL326877 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL5698359 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL327161 | 0.94 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL2021533 | 0.94 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL3502856 | 0.94 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL160176 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| SCHEMBL6265990 | 0.90 | SMN1; SMN2 (0.60) | SMN1; SMN2NR5A2NR5A1FABP3MAPT | |
| Hydrochloric Acid SCHEMBL15093812 | 0.88 | FABP3 (0.70) | SMN1; SMN2NR5A2NR5A1FABP3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150222-A1 | IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME | MANA BIO LTD. (IL) | 2024-07-18 | — | — | WO | claimed |
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | EYEGENE INC. (KR) | 2024-05-23 | — | — | US | claimed |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | EYEGENE INC. (KR) | 2024-05-09 | — | — | US | claimed |
| EP-4356933-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | Eyegene, Inc. (KR) | 2024-04-24 | — | — | EP | claimed |
| US-20240115513-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | THE JOHNS HOPKINS UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| WO-2024054020-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | 아이진 주식회사 | 2024-03-14 | — | — | WO | claimed |
| EP-4313003-A1 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | Recode Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117440834-A | Composition for in vivo delivery of ribonucleic acid and method for producing the same | 艾金株式会社 | 2024-01-23 | — | — | CN | claimed |
| EP-4306132-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPARATION METHOD THEREFOR | Eyegene Inc. (KR) | 2024-01-17 | — | — | EP | claimed |
| EP-4306126-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | Eyegene Inc. (KR) | 2024-01-17 | — | — | EP | claimed |
| EP-2193204-B1 | COMPOSITIONS COMPRISING LIPOPHOSPHORAMIDES AND THEIR USES IN GENE THERAPY | UNIV BRETAGNE OCCIDENTALE (FR) | 2011-08-31 | — | — | EP | claimed |
| WO-2011098578-A2 | LIPOSOME SYSTEM FOR OCULAR ADMINISTRATION | BIONEER A/S (DK) | 2011-08-18 | — | — | WO | claimed |
| US-20110160282-A1 | NUCLEIC-ACID PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2011-06-30 | — | — | US | claimed |
| EP-1590006-B1 | ULTRASOUND CONTRAST AGENTS AND PROCESS FOR THE PREPARATION THEREOF | BRACCO SUISSE SA (CH) | 2010-09-08 | — | — | EP | claimed |
| US-7745419-B2 | Pharmaceutical composition for treating cancer | KOREA UNIVERSITY INDUSTRIAL & ACADEMIC COLLABORATION FOUNDATION (KR) | 2010-06-29 | — | — | US | claimed |
| WO-2009104896-A2 | NUCLEIC-ACID PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY | 고려대학교 산학협력단 (KR) | 2009-08-27 | — | — | WO | claimed |
| US-20090081282-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER | KOREA UNIVERSITY INDUSTRIAL & ACADEMIC COLLABORATION FOUNDATION (KR) | 2009-03-26 | — | — | US | claimed |
| US-20080131455-A1 | Antigen Delivery Compositions And Methods Of Use | PDS BIOTECHNOLOGY CORPORATION (US) | 2008-06-05 | — | — | US | claimed |
| US-20070293449-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF DOUBLE-STRANDED RNA | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-7303881-B2 | Antigen delivery compositions and methods of use | PDS BIOTECHNOLOGY CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131455-A1 | Antigen Delivery Compositions And Methods Of Use | CD74, CD47, HAVCR2 | SMN1; SMN2 1203/4885NR5A2 3471/4885NR5A1 3641/4885 |
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | ACE2, SARS1, RBM22 | SMN1; SMN2 480/4885NR5A2 2098/4885NR5A1 3502/4885 |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | RTCB, RRP1B, PRPF6 | SMN1; SMN2 817/4885NR5A2 4748/4885NR5A1 3917/4885 |
| US-20070293449-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF DOUBLE-STRANDED RNA | ADAR, POLRMT, MTREX | SMN1; SMN2 400/4885NR5A2 3348/4885NR5A1 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.